Built from Dexcom Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$80.35+0.6%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Company outlook: revenue of $5.2B to $5.3B for Fiscal year 2026 — up 12.1% on a year earlier
Just reported
From Dexcom's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$1.34B
+11% y/y
+2.8% q/q
Guided
—
No guide given
Actual
$0.72
+2.9% y/y
+13% q/q
Guided
—
No guide given
Actual
$327.2M
+35% y/y
+2.8% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Dexcom is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade B+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Dexcom Inc.’s grade history. The other 39 go back to November 2016.
